Stocktoria

Spyre Therapeutics, Inc. SYRE

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2016-04-07 · LEI

Spyre Therapeutics, Inc. statistics & valuation

Market cap$7.6B
P / B10.7×
Return on equity-21.7%
Return on capital-29.1%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
2016201720182019202020212022202320242025
Operating margin (%)
-473.30% -531.70% -1169.30% -350.30% -3640.20% -27348.00% 2016201720182019202020212022202320242025
Return on equity (%)
-34.50% -54.10% -65.80% -130.20% -57.90% -78.40% -166.60% -184.10% -40.20% -21.70% 2016201720182019202020212022202320242025
Shares outstanding
13.4M 16.7M 24.1M 29.1M 53.4M 49.4M 3.4M 36.1M 60.3M 78.2M 2016201720182019202020212022202320242025
Net debt ($)
2016201720182019202020212022202320242025
Share buybacks ($)
2016201720182019202020212022202320242025
Return on assets (%)
-32.40% -48.60% -57.00% -94.10% -50.10% -59.90% -117.80% -99.10% -34.20% -20.00% 2016201720182019202020212022202320242025
Free cash flow margin (%)
-411.70% -484.80% -838.90% -289.70% -3442.80% -11276.50% 2016201720182019202020212022202320242025
Debt / equity (×)
2016201720182019202020212022202320242025
EPS ($)
-$1.52 -$25.02 -$24.86 -$49.12 2016201720182019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating margin——-27348.0%-3640.2%-350.3%——-1169.3%-531.7%-473.3%
Net margin——-38238.1%-3598.8%-351.1%——-1140.6%-523.3%-468.8%
FCF margin——-11276.5%-3442.8%-289.7%——-838.9%-484.8%-411.7%
Return on assets-20.0%-34.2%-99.1%-117.8%-59.9%-50.1%-94.1%-57.0%-48.6%-32.4%
Return on equity-21.7%-40.2%-184.1%-166.6%-78.4%-57.9%-130.2%-65.8%-54.1%-34.5%
Current ratio13.2511.2610.684.254.919.114.067.499.7716.75

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.